Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2013 Apr;69(4):1037-9.
doi: 10.1007/s00228-012-1414-3. Epub 2012 Oct 3.

Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy

Jean-François Desaphy, Anna Modoni, Mauro Lomonaco, Diana Conte Camerino
Case Reports

Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy

Jean-François Desaphy et al. Eur J Clin Pharmacol. 2013 Apr.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Chair test. The functional chair test was performed at the same time of day, in a comfortable room with an ambient temperature of 25 °C. Both patients were asked to rise from a chair after a 5 min rest and perform three turns around the chair as quickly as they could (T1). The performance was repeated 5 min later (T2) and once again without any rest (T3), in order to evaluate the warm-up phenomenon or paradoxical worsening. The time spent to perform the exercise was measured with a stopwatch. The test was performed when the patient was taking mexiletine, then 12 (test #1) and 21 (test #2) months after the introduction of flecainide. The test showed a remarkable improvement in both mother and son with flecainide treatment
See this image and copyright information in PMC

References

    1. Matthews E, Fialho D, Tan SV, Venance SL, Cannon SC, Sternberg D, Fontaine B, Amato AA, Barohn RJ, Griggs RC, Hanna MG, the CINCH Investigators The non-dystrophic myotonias: molecular pathogenesis, diagnosis, and treatment. Brain. 2010;133:9–22. doi: 10.1093/brain/awp294. - DOI - PMC - PubMed
    1. Desaphy JF, De Luca A, Didonna MP, George AL, Jr, Conte Camerino D. Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block. J Physiol. 2004;554:321–334. doi: 10.1113/jphysiol.2003.046995. - DOI - PMC - PubMed
    1. Lerche H, Heine R, Pika U, George AL, Jr, Mitrovic N, Browatzki M, Wei T, Rivet-Bastide M, Franke C, LoMonaco M, Ricker K, Lehmann-Horn Human sodium channel myotonia: slowed channel inactivation due to substitutions for a glycine within the III–IV linker. J Physiol. 1993;470:13–22. - PMC - PubMed
    1. Mitrovic N, George AL, Jr, Lerche H, Wagner S, Fahlke C, Lehmann-Horn F. Different effects on gating of three myotonia-causing mutations in the inactivation gate of the human muscle sodium channel. J Physiol. 1995;487.1:707–114. - PMC - PubMed
    1. Trip J, Drost G, Ginjaar HB, Nieman FH, van der Kooi AJ, de Visser M, van Engelen BG, Faber CG. Redefining the clinical phenotypes of non-dystrophic myotonic syndromes. J Neurol Neurosurg Psychiatry. 2009;80:647–652. doi: 10.1136/jnnp.2008.162396. - DOI - PubMed

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources